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The Consumer Protection Act (No. 68 of 2008) (CPA)1 aims to 
protect and develop the social and economic welfare of consumers, 
in particular potentially vulnerable consumers.2 It applies to all 
transactions in South Africa that involve the supply of goods or 
services,3 unless exempted.4 The definition of a ‘consumer’ includes 
a patient.5 Despite its noble objectives the application of the Act to 
the health care sector creates practical challenges and uncertainties. 
Health care establishments and practitioners must ensure that they 
comply with the CPA’s onerous and stringent requirements.
The CPA establishes eight fundamental consumer rights: right 
to equality in the consumer market;6 privacy;7 choice;8 disclosure 
and information;9 fair and responsible marketing;10 fair and honest 
dealing;11 fair, just and reasonable terms and conditions;12 fair value, 
good quality and safety;13 and the right to hold the supplier accountable 
to consumers.14 If the CPA conflicts with other concurrent health 
care legislation (e.g. the Health Pofessions Act No. 56 of 1974 or the 
Medical Schemes Act No. 131 of 1998), the Act offering the greater 
protection to the consumer will apply,15 which, without exception, 
favours the consumer-orientated CPA.
Key definitions illustrate the nature of the application of this 
legislation in the context of health care. ‘Service’ refers to work 
performed by a person for the direct or indirect benefit of another, 
including the provision of information, advice or consultation, e.g. 
consultation with a health practitioner; medical advice rendered by 
the practitioner, or any medical intervention, such as an operation; 
and the undertaking, underwriting or assumption of risk by a 
person on behalf of another.16 This includes medical scheme cover 
and services provided under risk-sharing arrangements. A health 
care establishment or practitioner will, depending on the context, 
also be regarded as a ‘supplier’ in terms of the CPA. A ‘supplier’ 
is a person who markets goods or services, including individuals, 
juristic persons, partnerships, trusts, organs of state and public-
private partnerships.3 ‘Market’ in this context means to ‘supply’ or 
‘promote’ goods or services,3 whereas ‘supply’ means to sell services, 
or to perform services or cause them to be performed or provided. In 
relation to goods, ‘supply’ means to sell, rent, exchange or hire goods 
in exchange for money. ‘Goods’ are broadly defined and include 
‘anything marketed for human consumption’ , 3 including not only 
medicines, but also devices and consumables.
Thus, practically all interactions between patients, health care 
providers and medical schemes will fall within the ambit of a CPA 
transaction. Depending on the context (e.g. when ordering goods 
from another supplier), patients and other health care providers may 
qualify as either consumers or ‘suppliers’. (It is doubtful whether 
medical schemes will be regarded as consumers, since the CPA 
does not apply to entities the asset value or net turnover of which 
exceeds the threshold of R2 million.17) Patients are consumers and 
beneficiaries of services (e.g. medical scheme dependants).
The CPA provides that a regulatory authority (e.g. the Health Professions 
Council of South Africa) may apply to the Minister for an industry-wide 
exemption from provisions of the Act on the grounds that these provisions 
overlap or duplicate a regulatory scheme already in existence in terms of 
national legislation, treaty, international law or convention.18
No-fault liability for damage caused 
by goods
A contentious issue of the CPA is its strict or no-fault liability for 
damage caused by goods. A consumer has the right to expect that 
goods are: (i) reasonably suitable for the purposes for which these 
are generally intended; (ii) in good working order, free from defects; 
and (iii) usable and durable for a reasonable period of time.19 The 
consumer is also entitled to the performance of services in a manner 
and of a quality that persons are generally entitled to expect.20 It also 
provides for an implied warranty in each transaction or agreement 
relating to the supply of goods to the consumer, and that the importer, 
distributor and the retailer each warrants that the goods comply with 
the requirements and standards comtemplated in the CPA.21 These 
provisions applied to the health care context are obvious and extend 
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to transactions from medical treatment and procedures (including 
the implantation of a prosthesis) to the dispensing of medicines.
The CPA provides that the producer or importer, distributor or 
retailer of goods is liable for harm caused as a result of the supply 
of unsafe goods; a product failure, defect or hazard in goods; or 
insufficient instructions or warnings to the consumer relating to 
any hazard arising from or associated with the use of the goods, 
irrespective of whether the harm is the result of negligence on the part 
of any of these parties.22 This changes the legal position prior to the 
CPA dramatically, as previously consumers relied on contractual 
remedies against the manufacturer whose product caused them 
harm, or alternatively had to institute civil claims against the 
manufacturer. The consumer, had to, among others, prove fault on 
the part of the manufacturer. This posed a difficult hurdle, as there 
may not have been fault present in the production process; the 
manufacturer may have been difficult to identify, or the consumer 
may not have had insight into the production process.14 The no-fault 
liability introduced into consumer legislation may open the litigation 
floodgates. To be successful in a product liability claim in terms of the 
CPA, a plaintiff need only prove that the relevant goods (that were 
unsafe, defective, hazardous or contained inadequate instructions 
pertaining to a hazard) have caused harm. This provision, however, 
does not specifically refer to a supplier, e.g. a specialist who supplies 
an implant for implantation may be regarded as a ‘retailer’ under this 
provision. Although medicines differ from ordinary commodities 
and are not regarded as commodities of trade,23 all medicines, 
including prescribed and over-the-counter medicines, are subject to 
the provisions of the CPA.
A supplier of services who in conjuction with performing these 
services also applies, supplies, installs or provides access to any 
goods, is regarded as a supplier of those goods to the consumer for 
the purpose of this strict liability provision.24 Thus, in the healthcare 
context no-fault liability may arise in respect of a range of health 
practitioners who supply, provide access to, or implant prostheses 
or medical devices. Since the claimant can sue anyone in the supply 
chain and hold them liable for harm and cost, and since health 
professionals who delivered the care are the most easily (and usually 
the only) identifiable person in the supply chain, they can be held 
strictly liable for the cost of the damages that may follow. 25 This 
applies, for example, to defective prostheses, implants, pacemakers 
and medications for which a claim may be brought if damage results. 
This provision is to protect the consumer (patient) against defective 
or inferior implants, as they often have no choice but to rely on the 
supplier’s (or health care provider’s) choice of goods. If more than one 
person is liable in terms of this provision (which will depend on the 
individual facts), their liability will be jointly and severally,26 which 
means that they may be liable individually or as a group. Consumers 
may decide to sue the producer, importer, distributor or retailer, or 
all of them (which may include the health care provider, if part of the 
supply chain, e.g. as ‘retailer’).27
The type of harm covered by the no-fault liability includes 
death, injury or illness, or pure economic loss (e.g. loss of earnings) 
caused by the resultant harm.28 Although the causal link between 
the defective goods and the harm or death that resulted must be 
established on a balance of probabilities, the traditional common-
law obstacle of proving negligence no longer applies, which makes 
proving product liability much easier. The consumer still remains at 
risk of an adverse costs order if he or she is unsuccessful in court.29
Provisions of the CPA allow for class actions, including consumer 
protection groups, which allows a number of claimants to institute 
a class action,30 based on a well-defined question of fact or law. 
Although the CPA provides for a mechanism through which 
consumer complaints can be addressed by the National Consumer 
Commission, National Consumer Tribunal, relevant ombud or 
consumer courts, the only forum with the appropriate authority to 
resolve a product liability claim will be a civil court. In addition to the 
removal of the fault requirement, contingency fee arrangements will 
facilitate product liability litigation.29,31 Class actions may be costly to 
suppliers, who will need sufficient liability insurance for such claims.
However, defences are available to those against whom no-fault 
liability claims are brought, e.g. no-fault liability does not apply if: 
(i) the unsafe feature of the product, or the hazard, failure or defect, 
results from compliance with any public regulation; (ii) the alleged 
unsafe feature, hazard, failure or defect did not exist in the goods 
when they were supplied to another person alleged to be liable; (iii) it 
is unreasonable to expect the distributor or retailer to have detected 
the unsafe feature, failure, defect or hazard; or (iv) the claim for 
damages is brought 3 years after the said death or injury occurred.32
Conclusion
With patients as ‘consumers’ in terms of the CPA, doctors are within 
the chain that extends from manufacturer to consumer. The CPA’s 
introduction of strict liability poses problems in the health care 
context. Health care providers and establishments must review their 
medical malpractice insurance to ensure that it includes sufficient 
cover for product liability (to cover the risk event, quantum of 
damages and legal costs pertaining to claimant and defence costs) 
created under the CPA. Suppliers should also seriously consider 
improving quality controls, and if part of a supply chain, obtain 
appropriate indemnities from all the other parties. Although medical 
defence organisations continue to assist members faced with medico-
legal problems arising from clinical practice, the increased exposure 
of members to product liability will undoubtedly significantly 
influence membership fees in the medium term. Only time will tell 
how far-reaching the Act’s influence on the health care sector will be.
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